NUVB ▲ +4.2% - Nuvation Bio Inc. $NUVB - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio shares rose 4.2% following FDA approval of a supplemental application for IBTROZI (taletrectinib) that includes updated duration-of-response data in treatment-naïve patients with advanced ROS1-positive non-small cell lung cancer. The regulatory clearance expands the commercial positioning of the company's key oncology asset with improved clinical evidence. 17-SEP-2026 07:31 AM ET